This study was conducted to investigate the effect of body condition (BC) and other characteristics on estrus responses post altrenogest treatment and on reproductive performance in 161 gilts, bred artificially, treated with 20 mg altrenogest orally for 18 consecutive days. Parameters recorded at the beginning of altrenogest treatment included age and body weight. Backfat (BFT) and muscle thickness (MT), both defining BC, puberty status and uterine size (UtS, based on cross-sectional areas of the uterine horns) were recorded by real-time-ultrasound (RTU), and BFT, along with MT together with ovary status, were recorded again at the end of altrenogest treatment. Estrus rate (ER), interval of last altrenogest treatment onset of estrus (ATOE), conception (CR) and farrowing (FR) rates, litter size characteristics (total, life, and still born piglets; TB, LB, SB) and individual piglet birth weights (IPWs) were recorded. Average age and weight were 252.6 ± 7.5 days and 153.0 ± 12.4 kg, respectively. BFT and MT were 0.9 ± 0.2 and 6.0 ± 0.4 cm, respectively, at the beginning of altrenogest treatment, and similar at the end. 147 gilts were determined as pubertal (PUB) and 14 prepubertal (PRE). All gilts only had follicles of 3.2 ± 0.4 mm on average at the end of altrenogest treatment. ER, ATOE, CR, FR, TB, LB, SB and IPW were 99.4%, 5.9 ± 0.5 days, 100%, 95.6%, 18.1 ± 2.6, 17.4 ± 2.5, 0.7 ± 1.0, 1.3 ± 0.2 kg, respectively. PUB and PRE did not differ, or only marginally differed, in all recorded parameters. BC or pubertal status did not have a great impact on the efficacy of altrenogest treatment or reproductive performance. However, UtS was significantly smaller in PRE than in PUB (0.51 ± 0.15 cm and 1.63 ± 0.48 cm, respectively). There was a very slight significant relationship between UtS and LB (r = 0.19, = 0.03) and a tendency towards TB (r = 0.15, = 0.09). In conclusion, under the conditions of this study, BC, age and pubertal status did not have an effect on the efficacy of altrenogest or the reproductive performance of hyper-prolific gilts of Danish genetic origin, but uterine size may have had a positive effect.

Download full-text PDF

Source
http://dx.doi.org/10.3390/ani15050623DOI Listing

Publication Analysis

Top Keywords

altrenogest treatment
32
reproductive performance
16
treatment reproductive
12
altrenogest
10
body condition
8
characteristics estrus
8
estrus responses
8
responses post
8
post altrenogest
8
treatment
8

Similar Publications

This study was conducted to investigate the effect of body condition (BC) and other characteristics on estrus responses post altrenogest treatment and on reproductive performance in 161 gilts, bred artificially, treated with 20 mg altrenogest orally for 18 consecutive days. Parameters recorded at the beginning of altrenogest treatment included age and body weight. Backfat (BFT) and muscle thickness (MT), both defining BC, puberty status and uterine size (UtS, based on cross-sectional areas of the uterine horns) were recorded by real-time-ultrasound (RTU), and BFT, along with MT together with ovary status, were recorded again at the end of altrenogest treatment.

View Article and Find Full Text PDF

Genetic selection for hyperprolific sows resulted in higher proportion of low birthweight piglets and greater birthweight variation within the litter, increasing preweaning mortality. There is evidence that altrenogest supplementation improves post-weaning reproductive performance through higher ovulation rates, and increased embryo survival. This study aimed to evaluate the impacts of altrenogest supplementation during the last week of lactation in primiparous sows on subsequent reproductive performance.

View Article and Find Full Text PDF

Altrenogest, also known as allyltrenbolone, is a synthetic form of progesterone used therapeutically to suppress unwanted symptoms of estrus in female horses. Altrenogest affects the system by decreasing levels of endogenous gonadotrophin and luteinizing and follicle-stimulating hormones, which in turn decreases estrogen and mimics the increase of progesterone production. This results in more manageable mares for training and competition alongside male horses while improving the workplace safety of riders and handlers.

View Article and Find Full Text PDF

A new hormonal protocol supports early development of in vitro-produced embryos after transfer to anoestrus mares.

Reprod Domest Anim

October 2024

Departamento de Medicina Animal, Grupo de Investigación Medicina Interna Veterinaria (MINVET), Instituto de Investigación INBIO G+C, Facultad de Veterinaria, Universidad de Extremadura, Cáceres, Spain.

The present study aimed to evaluate whether primed anoestrus mares are suitable recipients for embryos produced by intracytoplasmic sperm injection (ICSI). Anoestrus was confirmed in four mares and daily doses of oestradiol benzoate (6 mg in total) over 5 days were administered; after 3 days of rest, oral altrenogest was administered at 0.088 mg/kg and embryos (1 to 5 embryos per mare; 15 in total) were transferred 3.

View Article and Find Full Text PDF

Pharmacokinetics of Two Formulations of Altrenogest Administered to Mares.

Drug Test Anal

September 2024

School of Agricultural, Environmental and Veterinary Sciences, Charles Sturt University, Wagga Wagga, New South Wales, Australia.

Altrenogest is a synthetic progestin that suppresses reproductive behaviours and assists pregnancy maintenance in female horses. Two formulations are available, a 'weekly' intramuscular injection and a daily oral formulation. Altrenogest administration has returned positive swabs for steroids; consequently, using injectable altrenogest in racing mares is prohibited.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!